Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608521 | 1.00 | MAPK14 (0.67) | MAPK14L3MBTL1LCKSRCKDR | |
| SCHEMBL4609483 | 0.95 | MAPK14 (0.65) | MAPK14LCKSRCKDR | |
| SCHEMBL4609475 | 0.95 | MAPK14 (0.65) | MAPK14LCKSRCKDR | |
| SCHEMBL4609638 | 0.94 | MAPK14 (0.64) | MAPK14LCKSRCKDR | |
| SCHEMBL4609646 | 0.94 | MAPK14 (0.64) | MAPK14LCKSRCKDR | |
| SCHEMBL4608888 | 0.93 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL4608892 | 0.93 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL4610169 | 0.92 | MAPK14 (0.68) | MAPK14LCKSRCKDRKDM4E | |
| SCHEMBL4609551 | 0.92 | MAPK14 (0.68) | MAPK14LCKSRCKDRPLK1 | |
| SCHEMBL4609559 | 0.92 | MAPK14 (0.68) | MAPK14LCKSRCKDRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885L3MBTL1 4187/4885LCK 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.